RxDoctor Payments Data

David Kennedy, MD

Internal Medicine · Austintown, OHNPI 1235120288

Payments from drug & device makers

$10,295in general payments, 2019–2025

Across 736 payments — averaging $13.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$958
  • AstraZeneca$915
  • Amarin Pharma, Inc.$809
  • Pfizer$691
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$10,14699%
  • Education$1491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,295 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$59,135
Medicare patients
253
Services billed
866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$115,880
JardianceEmpagliflozin64$68,023
MounjaroTirzepatide48$49,933
OzempicSemaglutide33$43,853
JanuviaSitagliptin Phosphate40$41,452
RybelsusSemaglutide24$40,961
EntrestoSacubitril/Valsartan35$33,999
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$26,606
FarxigaDapagliflozin Propanediol22$24,079
XareltoRivaroxaban23$19,714
Breo ElliptaFluticasone/Vilanterol26$10,335
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,188
LinzessLinaclotide14$7,973
MyrbetriqMirabegron12$7,325
Lantus SolostarInsulin Glargine,hum.Rec.Anlog52$6,852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$691$115,880119 claims
Novo NordiskOzempic, Rybelsus$1,334$84,81457 claims
Boehringer IngelheimJardiance$386$68,02364 claims
AstraZenecaBreztri Aerosphere, Farxiga$915$50,68456 claims
Lilly USA, LLCMounjaro$958$49,93348 claims
MerckJanuvia$342$41,45240 claims
NovartisEntresto$191$33,99935 claims
GSKBreo Ellipta, Trelegy Ellipta$274$20,52337 claims
Johnson & JohnsonXarelto$503$19,71423 claims
AbbVieLinzess, Synthroid$1,529$9,84054 claims
Astellas Pharma US IncMyrbetriq$247$7,32512 claims
Esperion Therapeutics, Inc.Nexletol$126$5,46213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Austintown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →